Breast cancer prognosis is steadily improving due to early detection of primary cancer in
screening programs and revolutionizing treatment development. In the metastatic setting …

Molecular imaging, such as positron emission tomography (PET), is increasingly used as
biomarker to predict and assess treatment response in breast cancer. The number of …

Purpose To provide an organized, international, state-of-the-art, and multidisciplinary
guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and …

This study aimed to compare CE-CT and 2-[18F] FDG-PET/CT for response monitoring
metastatic breast cancer (MBC). The primary objective was to predict progression-free and …

Female breast cancer (BC) is one of the most diagnosed cancers and causes of cancer-
related deaths in women, second only to lung cancer in Unites States. The American Cancer …

Recent developments in hybrid SPECT/CT systems and the use of cadmium-zinc-telluride
(CZT) detectors have improved the diagnostic accuracy of bone scintigraphy. These …

The study aimed to compare the metastatic pattern of breast cancer and the intermodality
proportion of agreement between [18F] FDG-PET/CT and CE-CT. Women with metastatic …

We evaluated the cost-effectiveness of 2-[18F] FDG-PET/CT compared to CE-CT for
response monitoring in metastatic breast cancer (MBC) patients. The study included 300 …

Positron Emission Tomography (PET) has been growing in usage for patients with breast
cancer, due to an increased number of FDA-approved PET radiotracers pertinent to patients …

Breast cancer is the most frequently diagnosed cancer and leading cause of cancer-related
deaths worldwide. Timely decision-making that enables implementation of the most …